전임상 CRO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Preclinical CRO Market size is expected to reach USD 14.02 Billion in 2034 from USD 6.83 Billion (2025) growing at a CAGR of 8.31% during 2026-2034.

The Global Preclinical CRO Market is expanding rapidly due to increasing pharmaceutical and biotechnology research activities. Companies are outsourcing preclinical studies to reduce operational costs and accelerate drug development timelines. Rising investments in novel therapeutics, including biologics and gene therapies, are fueling demand for specialized research services. Growing complexity of drug pipelines is further strengthening the need for expert contract research organizations.

Technological advancements in in vitro testing, animal models, and data analytics are enhancing research efficiency. Regulatory requirements for safety and efficacy testing are becoming more stringent, driving reliance on experienced CRO partners. Emerging biotech startups prefer outsourcing to focus on core competencies. Additionally, increased collaboration between academic institutions and CROs is boosting innovation and research capabilities.

Looking ahead, the market is expected to benefit from rising R&D expenditure globally. Adoption of advanced technologies such as AI-driven drug discovery and predictive toxicology will likely expand service offerings. Asia-Pacific is anticipated to emerge as a significant growth region due to cost advantages and expanding research infrastructure. Continuous innovation and strategic partnerships are expected to sustain long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

• Bioanalysis and DMPK studies
• Toxicology Testing
• Compound Management
• Process R&D
• Chemistry
• Safety Pharmacology
• Others

By Model Type

• Patient Derived Organoid (PDO) Model
• Patient Derived Xenograft Model

By End-use

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

COMPANIES PROFILED

• WuXi AppTec Inc, Labcorp Laboratory Corporation of America Holdings, Eurofins Scientific SE, Medpace Holdings Inc, Charles River Laboratories International Inc, Intertek Group plc, PPD Thermo Fisher Scientific Inc, ICON plc formerly including PRA Health Sciences, Covance LabCorp, Crown Bioscience
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PRECLINICAL CRO MARKET: BY SERVICE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service
• 4.2. Bioanalysis and DMPK studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Toxicology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Compound Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Process R&D Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Safety Pharmacology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRECLINICAL CRO MARKET: BY MODEL TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Model Type
• 5.2. Patient Derived Organoid (PDO) Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Patient Derived Xenograft Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRECLINICAL CRO MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Government and Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Medical Device Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRECLINICAL CRO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service
  • 7.2.2 By Model Type
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service
  • 7.3.2 By Model Type
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service
  • 7.4.2 By Model Type
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service
  • 7.5.2 By Model Type
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service
  • 7.6.2 By Model Type
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PRECLINICAL CRO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 WuXi AppTec Inc
  • 9.2.2 Labcorp (Laboratory Corporation Of America Holdings)
  • 9.2.3 Eurofins Scientific SE
  • 9.2.4 Medpace Holdings Inc
  • 9.2.5 Charles River Laboratories International Inc
  • 9.2.6 Intertek Group Plc
  • 9.2.7 PPD (Thermo Fisher Scientific Inc.)
  • 9.2.8 ICON Plc (Formerly Including PRA Health Sciences)
  • 9.2.9 Covance (LabCorp)
  • 9.2.10 Crown Bioscience